Ravulizumab and eculizumab reduce transfusions in adult patients with paroxysmal nocturnal hemoglobinuria: evidence from three real-world databases: TriNetX us EMR, TriNetX US claims and Komodo Health
Changes in hemoglobin measures observed in PNH patients treated with both c5 inhibitors ravulizumab and eculizumab: real-world evidence from a US-Based EMR network
Real-world healthcare utilization and clinical markers preceding dialysis in patients with primary hyperoxaluria (PH) in the United States (PO1317)
